Biomol Ther.  2022 Jan;30(1):90-97. 10.4062/biomolther.2021.077.

Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models

• Ham HJ
• Yeo IJ
• Jeon SH
• Lim JH
• Yoo SS
• Son DJ
• Jang SS
• Lee H
• Shin SJ
• Han SB
• Yun JS
• Hong JT

• KMID: 2524151
• DOI: http://doi.org/10.4062/biomolther.2021.077

Abstract

Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson’s disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whether botulinum neurotoxin A (BoNT-A) was effective for the treatment of PD through its anti-neuroinflammatory effects and the modulation of acetylcholine and dopamine release. We found that BoNT-A ameliorated MPTP and 6-OHDA-induced PD progression, reduced acetylcholine release, levels of IL-1β, IL-6 and TNF-α as well as GFAP expression, but enhanced dopamine release and tyrosine hydroxylase expression. These results indicated that BoNT-A had beneficial effects on MPTP or 6-OHDA-induced PD-like behavior impairments via its anti-neuroinflammation properties, recovering dopamine, and reducing acetylcholine release.

Keyword

Parkinson’s disease; Botulinum toxin A; Anti-neuroinflammation